Asia Pacific Bovine Respiratory Disease Treatment Market Research Report - By Type of Treatment and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis (2025 to 2033)
The APAC Bovine Respiratory Disease Treatment Market Size was valued at USD 30.77 million in 2024. The APAC Bovine Respiratory Disease Treatment Market Size is expected to have 30.05% CAGR from 2025 to 2033 and be worth USD 327.43 million by 2033 from USD 40.02 million in 2025.
Bovine Respiratory Disease (BRD) is a multifactorial illness affecting cattle, primarily caused by a combination of viral and bacterial pathogens. It is one of the most economically significant health challenges in the livestock industry across the Asia-Pacific (APAC) region. The disease predominantly affects calves and feedlot cattle, leading to reduced weight gain, increased mortality, and higher treatment costs. In APAC, where countries like India, China, and Australia maintain large cattle populations, BRD poses a major threat to animal health and agricultural productivity.
The APAC Bovine Respiratory Disease Treatment Market includes a wide range of therapeutic interventions, including antibiotics, anti-inflammatory drugs, vaccines, and supportive care products.
According to the Food and Agriculture Organization (FAO), the total cattle population in the APAC region exceeded 450 million in 2023, underlining the vast potential for disease outbreaks and subsequent demand for effective treatments. As per the World Organisation for Animal Health (WOAH), BRD contributes significantly to morbidity rates in feedlots across several APAC countries, particularly during seasonal transitions or periods of environmental stress. This growing awareness among farmers and agribusinesses about early diagnosis and preventive healthcare has spurred investments in advanced treatment options, shaping a dynamic and evolving market landscape.
The expansion of the cattle population across the Asia-Pacific region has directly fueled the demand for bovine respiratory disease (BRD) treatments. Countries such as India, China, and Indonesia have witnessed steady growth in their livestock sectors due to rising urbanization and increasing consumer demand for beef and dairy products.
This surge in cattle numbers has heightened the risk of disease transmission, especially in densely populated feedlots and dairy farms.
Moreover, changing dietary preferences are driving up meat consumption across the region. With more animals entering the food supply chain, the likelihood of BRD outbreaks rises significantly. For instance, in Australia—home to one of the largest beef industries in the world—feedlot operators report that up to 20% of newly arrived cattle show symptoms of respiratory illness within the first few weeks of entry. These trends underline the urgent need for effective treatment protocols and preventive strategies, thereby stimulating market growth for BRD therapeutics.
Significant progress in veterinary medicine and a growing emphasis on preventive healthcare have played a pivotal role in expanding the APAC Bovine Respiratory Disease (BRD) Treatment Market. Governments and private stakeholders are increasingly investing in animal health infrastructure, promoting vaccination programs, and encouraging biosecurity measures.
In addition, pharmaceutical companies are launching next-generation vaccines targeting key BRD pathogens such as Mannheimia haemolytica , Pasteurella multocida , and Bovine Viral Diarrhea Virus (BVDV). For example, Zoetis and Merck Animal Health have introduced combination vaccines offering broader protection and easier administration, which has led to improved adoption rates.
As per the data from the Indian Council of Agricultural Research (ICAR), BRD vaccine usage in organized dairy farms increased by 17% between 2020 and 2023.
These developments signal a shift from reactive treatment toward proactive disease management, reinforcing the market’s growth trajectory and enhancing long-term sustainability in the APAC livestock industry.
One of the primary constraints impeding the growth of the APAC Bovine Respiratory Disease (BRD) Treatment Market is the lack of awareness and limited access to modern veterinary services in rural and remote farming areas. A significant portion of the livestock in countries like India, Nepal, and parts of Indonesia is managed by smallholder farmers who often rely on traditional practices rather than scientifically validated treatment protocols.
According to the Food and Agriculture Organization (FAO), over 70% of cattle in South and Southeast Asia are maintained by small-scale producers who have minimal exposure to advanced animal healthcare solutions.
This knowledge gap is further exacerbated by inadequate veterinary infrastructure and poor distribution networks for pharmaceutical products. In many regions, especially in rural China and parts of the Philippines, farmers do not have regular access to trained veterinarians or diagnostic facilities.
As reported by the International Livestock Research Institute (ILRI), only 35% of livestock keepers in low-income APAC regions consult professional veterinarians when signs of illness appear. Instead, they often resort to outdated remedies or delay treatment until the condition worsens, reducing the effectiveness of available therapies.
Besides, logistical challenges in transporting temperature-sensitive vaccines and biologics to remote locations hinder timely intervention. This results in lower treatment adherence and diminished market uptake of advanced BRD solutions, limiting overall market expansion despite rising disease prevalence.
The exorbitant cost of advanced BRD treatment options remains a significant barrier to widespread adoption across the Asia-Pacific region. Modern therapeutics such as combination vaccines, antimicrobial peptides, and injectable antibiotics often come with steep price tags that many small- and medium-sized farm operations cannot afford.
According to the Asian Development Bank (ADB), a significant portion, approximately 60% of livestock farmers in APAC operate on limited budgets, making them highly sensitive to pricing fluctuations in veterinary pharmaceuticals. In countries like Bangladesh and Myanmar, where per capita income remains low, farmers often prioritize basic sustenance over investing in costly disease prevention measures.
Compounding this issue are complex regulatory frameworks governing veterinary drug approvals, which vary widely across APAC nations. For instance, the process of registering new veterinary medicines in India involves multiple stages of clinical trials and compliance checks, significantly delaying market entry. Consequently, while innovative treatment options continue to emerge globally, their accessibility and affordability remain constrained in much of the APAC region, acting as a major restraint on market growth.
Government-backed initiatives aimed at improving animal health and boosting livestock productivity are creating significant opportunities for the APAC Bovine Respiratory Disease (BRD) Treatment Market. Several national governments in the region have launched subsidy programs and financial assistance schemes to promote the use of advanced veterinary medicines, vaccines, and diagnostics.
In India, for instance, the Ministry of Fisheries, Animal Husbandry & Dairying introduced the "National Animal Disease Control Programme (NADCP)" in 2019, allocating substantial funding to combat major livestock diseases, including BRD. As per the Department of Animal Husbandry and Dairying (DAHD), this initiative has led to a 25% increase in vaccine coverage in targeted states since its inception.
Similarly, in China, the Ministry of Agriculture and Rural Affairs has been actively supporting the procurement and distribution of essential livestock vaccines through its Central Animal Disease Prevention Fund.
In addition, in Thailand and Vietnam, local authorities have partnered with international organizations such as the Food and Agriculture Organization (FAO) to strengthen veterinary infrastructure and improve access to affordable treatment options.
These policy-driven efforts are not only enhancing disease prevention but also fostering a conducive environment for pharmaceutical companies to expand their reach, thereby unlocking new growth avenues in the APAC BRD treatment market
Advancements in digital agriculture and precision livestock farming technologies are opening new avenues for growth in the APAC Bovine Respiratory Disease (BRD) Treatment Market. The integration of wearable sensors, artificial intelligence (AI), and real-time health monitoring systems allows for early detection of respiratory distress in cattle, enabling timely intervention.
Moreover, precision medicine approaches are gaining traction, with researchers developing customized treatment regimens based on genetic profiling and pathogen-specific diagnostics.
In Australia, the Commonwealth Scientific and Industrial Research Organisation (CSIRO) has collaborated with veterinary biotech firms to introduce rapid diagnostic kits capable of identifying BRD-causing pathogens within minutes.
Also, mobile veterinary platforms and telemedicine services are expanding access to expert consultation, particularly in rural areas of India and Indonesia. These technological advancements are not only enhancing disease management outcomes but also driving demand for targeted therapeutics, positioning the APAC BRD treatment market for sustained innovation-led growth.
Antimicrobial resistance (AMR) is emerging as a critical challenge for the APAC Bovine Respiratory Disease (BRD) Treatment Market, driven by the overuse and misuse of antibiotics in livestock production. The excessive reliance on antimicrobials for both therapeutic and prophylactic purposes has accelerated the development of resistant bacterial strains, diminishing the efficacy of conventional treatment options.
According to the World Health Organization (WHO), Asia accounts for nearly 60% of global antibiotic consumption in food-producing animals, with countries like China and India being major contributors. In particular, tetracyclines, macrolides, and beta-lactams—commonly used in BRD treatment—are witnessing declining effectiveness due to rising resistance levels.
Regulatory bodies across the APAC region are responding with stricter guidelines on antibiotic usage. In China, the Ministry of Agriculture and Rural Affairs implemented a complete ban on the use of colistin in animal feed in 2020, following evidence linking its agricultural use to the emergence of resistant pathogens. Similarly, in India, the Department of Animal Husbandry and Dairying has mandated the labeling of antibiotics as “for therapeutic use only” and restricted their sale without veterinary prescriptions. These measures, while crucial for curbing AMR, have created treatment gaps, particularly in resource-constrained settings where alternative therapies remain inaccessible.
The growing pressure to reduce antibiotic dependence is prompting a shift toward alternative treatments such as phage therapy, probiotics, and immune modulators. However, the transition is slow due to limited awareness, high costs, and regulatory uncertainties, posing a substantial challenge to market growth in the near term.
Climate change and seasonal variability are increasingly influencing the epidemiology of Bovine Respiratory Disease (BRD) across the Asia-Pacific region, presenting a formidable challenge to the treatment market. Fluctuations in temperature, humidity, and rainfall patterns create favorable conditions for the proliferation of respiratory pathogens and weaken host immunity due to environmental stressors.
According to the Intergovernmental Panel on Climate Change (IPCC), the frequency and intensity of extreme weather events—such as heatwaves and monsoon anomalies—have increased in APAC, directly impacting livestock health.
For instance, in Australia, prolonged dry seasons followed by sudden heavy rains have led to spikes in BRD cases, particularly in northern cattle herds. Likewise, in India, unseasonal rainfall and erratic temperatures have disrupted traditional disease cycles, making BRD outbreaks more unpredictable.
These climatic shifts complicate disease forecasting and treatment planning, forcing veterinarians and farmers to adapt rapidly. However, the lack of region-specific predictive models and climate-resilient treatment strategies hampers effective response mechanisms, adding complexity to market growth and necessitating greater investment in adaptive research and development.
| REPORT METRIC | DETAILS |
| Market Size Available | 2024 to 2033 |
| Base Year | 2024 |
| Forecast Period | 2025 to 2033 |
| CAGR | 30.05% |
| Segments Covered | By Type of Treatment and Country. |
| Various Analyses Covered | Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC, PESTLE Analysis, Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
| Country Covered | China, India, Japan, South Korea, Australia, New Zealand, Thailand, Indonesia, Philippines, Vietnam, Singapore, Rest of APAC. |
| Market Leader Profiled | Zoetis Inc., Merck & Co. Inc., Bayer Corporation, Eli Lilly & Co, Merial S.A.S |
The Anti-Infectious Agents segment dominated the APAC Bovine Respiratory Disease (BRD) Treatment Market, accounting for 38.8% of total market revenue in 2024. This segment includes antibiotics such as florfenicol, tilmicosin, and ceftiofur, which are widely used in both prophylactic and curative treatments for BRD. The dominance of this category stems from its critical role in managing bacterial co-infections that often accompany viral respiratory illnesses in cattle.
One key driver behind the segment’s leadership is the high incidence of secondary bacterial infections in BRD-affected cattle. In countries like China and India, where large-scale cattle farming is prevalent, antibiotic use remains integral to disease control protocols. Apart from these, the growing adoption of feedlot systems—particularly in Australia and South Korea—has increased exposure risks, further boosting demand for anti-infectives. Another major factor fueling growth is the continued reliance on injectable formulations due to their rapid onset of action.
The Non-Steroidal Anti-Inflammatories (NSAIDs) segment is emerging as the fastest-growing within the APAC Bovine Respiratory Disease (BRD) Treatment Market, projected to expand at a CAGR of 9.4%. This accelerated growth is primarily attributed to the increasing emphasis on pain management and fever reduction in BRD-afflicted cattle, which enhances recovery rates and overall treatment efficacy.
A key driver for this segment is the rising awareness among farmers and veterinary professionals about the benefits of adjunctive therapy in BRD treatment. As reported by the Australian Department of Agriculture, Fisheries and Forestry, over 70% of feedlot operators in Australia now integrate NSAIDs into standard treatment protocols , recognizing their role in reducing lung lesions and improving weight gain outcomes. This trend is gradually gaining traction in other APAC countries such as Japan and South Korea, where animal welfare standards are more developed.
Moreover, regulatory support for responsible NSAID usage has encouraged broader adoption. These developments underscore a shift toward comprehensive, multi-modal treatment strategies, positioning NSAIDs as a rapidly expanding component of the BRD therapeutic landscape in the Asia-Pacific region.
India held a prominent position in the APAC Bovine Respiratory Disease (BRD) Treatment Market, contributing 18.3% of total regional market revenue in 2024. With the world’s largest livestock population, India faces persistent challenges related to bovine health, particularly in semi-intensive and unorganized dairy farms. BRD is a leading cause of morbidity among calves and young cattle, with outbreaks frequently reported during seasonal transitions.
One of the primary drivers of the market in India is the government’s active involvement in promoting animal healthcare through initiatives such as the National Animal Disease Control Programme (NADCP). In addition, the expansion of organized dairy farming, coupled with improved access to veterinary services, is fostering greater adoption of advanced treatment options.
Moreover, domestic pharmaceutical companies like Hester Biosciences and Indian Immunologicals have ramped up production of cost-effective vaccines and therapeutics, enhancing affordability for smallholder farmers.
China plays a central role in shaping the APAC Bovine Respiratory Disease (BRD) Treatment Market. As the second-largest beef producer in Asia and home to a large number of cattles, China faces substantial pressure from infectious livestock diseases, including BRD, which poses a significant threat to meat and dairy output. Outbreaks are especially common in intensive feedlot operations and large dairy farms, where overcrowding and environmental stressors heighten disease transmission risks.
A key factor driving market growth is the country’s aggressive push toward modernizing its livestock sector. Government-backed vaccination drives, particularly under the Central Animal Disease Prevention Fund, have played a crucial role in curbing BRD prevalence.
Furthermore, the presence of leading domestic veterinary pharmaceutical firms such as Qilu Animal Health and Huiyuan Animal Pharmaceutical has enhanced the availability of high-quality treatment options.
Australia ranks as one of the most advanced markets in the APAC Bovine Respiratory Disease (BRD) Treatment Market. As a global leader in beef exports, Australia maintains stringent livestock health standards, yet BRD remains a persistent concern, particularly in feedlots where stress-induced immune suppression increases susceptibility to infection.
A major growth driver in Australia is the widespread adoption of integrated disease management protocols. The country’s well-developed veterinary infrastructure ensures timely diagnosis and treatment, minimizing economic losses associated with poor weight gain and mortality.
Additionally, research institutions such as the Commonwealth Scientific and Industrial Research Organisation (CSIRO) are actively developing novel diagnostics and next-generation vaccines tailored to local pathogen strains. With strong regulatory oversight and a proactive approach to livestock health, Australia continues to serve as a benchmark for BRD treatment advancements across the Asia-Pacific region.
Japan holds a niche but influential position in the APAC Bovine Respiratory Disease (BRD) Treatment Market. While Japan's cattle population is relatively modest compared to countries like India or China, its highly mechanized and precision-driven livestock industry places a strong emphasis on preventive healthcare and disease surveillance. The country's premium Wagyu and dairy sectors, in particular, require stringent health protocols to maintain productivity and product quality.
A key driver of the BRD treatment market in Japan is the growing adoption of digital livestock monitoring technologies. These technologies have significantly improved disease response times and treatment accuracy, reducing economic losses from BRD outbreaks.
Also, Japan's regulatory environment supports the rapid approval and adoption of innovative veterinary medicines. With its high standards of animal care and technological sophistication, Japan continues to play a strategic role in advancing BRD treatment solutions across the Asia-Pacific region.
South Korea occupies a steadily growing position in the APAC Bovine Respiratory Disease (BRD) Treatment Market. The country’s livestock industry, though smaller in scale compared to China or India, is characterized by high levels of intensification and technological integration, making it particularly susceptible to respiratory disease outbreaks. With a growing demand for domestic beef and dairy products, South Korea has prioritized animal health to ensure sustainable livestock production.
A key factor driving market expansion is the increasing implementation of automated health monitoring systems in cattle farms. These advancements have led to a measurable decline in disease-related losses, enhancing farm profitability and food security.
Moreover, government initiatives aimed at strengthening veterinary healthcare infrastructure have played a crucial role in expanding treatment accessibility. These combined efforts are reinforcing South Korea’s position as an emerging market for advanced BRD treatment solutions in the Asia-Pacific region.
Notable companies leading the APAC Bovine Respiratory Disease Treatment Market are Zoetis Inc., Merck & Co. Inc., Bayer Corporation, Eli Lilly & Co, Merial S.A.S, Boehringer Ingelheim Vetmedica, Novartis Animal Health, Vibrac S.A., Ceva Sante Animale, and Vétoquinol S.A.
The competition in the APAC Bovine Respiratory Disease (BRD) Treatment Market is characterized by a mix of established multinational pharmaceutical companies and emerging domestic players striving to capture a larger share of the expanding animal health sector. While global leaders such as Zoetis, Merck Animal Health, and Boehringer Ingelheim maintain a strong foothold due to their extensive product portfolios and well-established distribution networks, regional players are increasingly stepping up with cost-effective alternatives and localized treatment solutions. This dynamic creates a highly competitive environment where innovation, affordability, and accessibility play pivotal roles in determining market success.
Pharmaceutical firms are focusing on developing region-specific formulations that address prevalent BRD strains in different APAC countries. Additionally, they are strengthening their presence through strategic acquisitions, partnerships with academic institutions, and participation in national livestock health programs. Meanwhile, local manufacturers are capitalizing on government incentives and rising demand from smallholder farmers to expand their reach. As the industry moves toward more sustainable and precision-based treatment approaches, companies must continuously adapt to evolving regulatory landscapes and consumer expectations to maintain a competitive edge.
Zoetis Inc.
Zoetis is a global leader in animal health and plays a dominant role in the APAC Bovine Respiratory Disease (BRD) Treatment Market. The company offers a comprehensive portfolio of vaccines, antibiotics, and anti-inflammatory drugs specifically designed for cattle health management. Zoetis has consistently invested in research and development to introduce innovative treatment solutions tailored to regional disease patterns. Its strong distribution network across Asia-Pacific ensures widespread availability of BRD therapeutics, particularly in key markets such as India, China, and Australia. By collaborating with local governments and veterinary institutions, Zoetis contributes significantly to improving livestock health standards and enhancing productivity in the region's growing dairy and beef sectors.
Merck Animal Health (MSD Animal Health)
Merck Animal Health is a major player in the APAC BRD treatment landscape, offering advanced vaccine formulations and antimicrobial therapies for respiratory disease management. The company emphasizes integrated disease control strategies that combine vaccination, diagnostics, and targeted therapeutics. Merck’s commitment to education and outreach programs has helped raise awareness among farmers and veterinarians about early detection and effective treatment protocols. In the Asia-Pacific region, its presence is particularly strong in countries like Japan, South Korea, and Australia, where regulatory frameworks support the adoption of high-quality veterinary medicines. Through continuous innovation and strategic partnerships, Merck plays a crucial role in shaping the future of bovine healthcare in APAC.
Boehringer Ingelheim Animal Health
Boehringer Ingelheim is a leading force in the global and APAC Bovine Respiratory Disease Treatment Market, known for its science-driven approach to animal health. The company provides a broad range of products including modified live vaccines, antimicrobials, and supportive care therapies aimed at preventing and treating BRD in cattle. Boehringer Ingelheim actively engages in capacity-building initiatives, working closely with veterinary professionals and agricultural agencies across APAC to improve disease surveillance and treatment adherence. Its presence spans both developed and emerging markets in the region, ensuring accessibility to essential BRD treatments even in rural settings. With a focus on sustainability and responsible use of veterinary medicines, Boehringer Ingelheim continues to strengthen its influence in the APAC market.
One of the primary strategies employed by key players in the APAC Bovine Respiratory Disease (BRD) Treatment Market is product innovation and pipeline development . Companies are continuously investing in research to create more effective vaccines, antibiotics, and supportive therapeutics tailored to regional pathogen strains. This includes the development of combination vaccines that offer broader protection against multiple BRD-causing agents, improving treatment efficiency and reducing the need for multiple interventions.
Another critical strategy is strategic collaborations and partnerships . Leading pharmaceutical firms are engaging in joint ventures with local manufacturers, research institutions, and government bodies to enhance product accessibility and distribution networks. These alliances help in aligning with national animal health programs and accelerating the adoption of advanced treatment protocols across diverse farming systems in the region.
Lastly, market expansion through digital integration is gaining prominence. Companies are leveraging digital platforms for farmer education, tele-veterinary services, and real-time disease monitoring. This approach not only improves disease management but also strengthens customer engagement, reinforcing brand loyalty and long-term market positioning.
In February 2024, Zoetis launched a new combination BRD vaccine specifically formulated for the APAC region, targeting prevalent viral and bacterial pathogens. This initiative aimed to provide broader immunity coverage and reduce the frequency of booster doses required in cattle herds.
In May 2024, Merck Animal Health partnered with a leading Indian veterinary research institute to develop an AI-based early warning system for detecting respiratory distress in cattle, supporting faster intervention and improved treatment outcomes.
In September 2024, Boehringer Ingelheim expanded its manufacturing facility in Australia to increase production capacity for injectable antimicrobials used in BRD treatment, ensuring better supply chain reliability across the region.
In November 2024, Hester Biosciences entered into a collaboration with a Japanese biotech firm to co-develop next-generation mucolytic formulations for enhanced respiratory disease management in dairy and beef cattle.
In January 2025, Virbac initiated a large-scale farmer education campaign across Southeast Asia, focusing on BRD prevention, responsible antibiotic use, and biosecurity measures to improve overall herd health and treatment compliance.
This research report segmented and sub-segmented the asia pacific bovine respiratory disease treatment market into the following categories.
By Treatment Type
By Country
Frequently Asked Questions
Major contributors include are India China Australia Japan Indonesia
Antibiotics (e.g., tulathromycin, florfenicol) Vaccines (for prevention) Anti-inflammatory drugs Supportive therapies (like fluids and electrolytes)
Increased investment in precision livestock farming Growth of e-veterinary services Rise in partnerships between governments and private companies to improve cattle health
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region